HEALTH

Robin Leedy and Associates wins three new OTC clients

BY Alaric DeArment

MOUNT KISCO, N.Y. — Public relations and digital marketing firm Robin Leedy and Associates has added three new clients, the firm said Tuesday.

RL&A said the clients were Matrixx Initiatives, which makes the Zicam family of pre-cold and nasal congestion products; Crosscare, which makes Colief Infant Drops for colic related to transient lactase deficiency; and Cirrus Healthcare Products, which makes EarPlanes air-pressure ear plugs, as well as AquaEars for children. The firm specializes in OTC, health and beauty aids and consumer lifestyle brands marketed to women.

"We’ve been developing social media and digital marketing initiatives for clients, particularly in the OTC and HBA space, that balance motivating messages and innovative, integrated platforms with [the Food and Drug Administration] and other regulatory requirements and brand marketing goals," RL&A president Robin Russo said.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Former Bayer executive wins CHPA award

BY Alaric DeArment

WASHINGTON — The former president of Bayer HealthCare’s Worldwide Consumer Care Division has won a lifetime-achievement award from a trade group focused on the OTC industry.

The Consumer Healthcare Products Association announced that it gave its Ivan D. Combe Lifetime Achievement Award to Gary Balkema at its annual executive conference in Naples, Fla.

Left to right: CHPA president and CEO Scott Melville; Gary Balkema; Jen Balkema; Rob Balkema; Donna Balkema; CHPA chairman Paul Sturman

"Gary’s commitment to the OTC industry was so great that in addition to his Bayer responsibilities, he served as chairman of CHPA from 1997 to 1999, leading the association with steadiness, pragmatism and balance," CHPA president and CEO Scott Melville said.

The organization noted that Balkema grew Bayer’s consumer care division from one focused regionally to a global one, quintupling sales and expanding operations to 140 countries, reversing a decline in sales following the acquisition of Sterling and helping make Bayer the second largest OTC company in the world.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

CHPA: OTC industry well-positioned to seize self-care opportunity

BY Michael Johnsen

NAPLES, Fla. — The Consumer Healthcare Products Association’s Annual Executive Conference was sold out for the first time since 2001, CHPA president and CEO Scott Melville told a packed morning session, and that is a strong prognosticator as to the health and vitality of the self-care industry. 

Melville identified many OTC-friendly regulations that will go into effect on Jan. 1, 2014 associated with the Patient Protection and Affordable Care Act. States will be required to cover smoking cessation under Medicaid; there will be a five-year national public education campaign promoting oral health; and there will be the expansion of Medicare coverage to include an annual wellness visit.

"I recently had [a wellness visit]," Melville said. "I walked out the door with two new supplement [recommendations]."

Looking ahead, business certainly looks promising. Greater consumer engagement and a focus on health cost-containment bodes well for the OTC industry noted Paul Sturman, CHPA chairman. "Today as many as 72% of Americans self-diagnose their ailments; 55% are visiting their doctors less frequently; and 69% are seeking a second or third opinion even after that doctor visit," Sturman said. 

Americans are looking for an OTC product as many as 26 times per year. They visit their doctors three times in a year. "By simple math that’s almost six-times the opportunity "to influence the customer," Sturman said. 

"The consumer is very much at the center of this … self-care ecosystem," he said. Healthcare is no longer "compartmentalized," and that expands the opportunity to communicate OTC value beyond on-shelf communications. "The point of self-care is the new point of purchase," Sturman added. 

There is also much future potential with a broadening switch paradigm, according to Sturman. "Switch creates all kinds of possibilities to every one of you in this room," he said. 

On the regulatory front, Melville outlined CHPA’s success in directly reaching teenagers most at risk to abuse medicines like dextromethorphan. "It is making a difference," he said. In the first five months CHPA has targeted teenagers with anti-abuse videos, 750,000 have downloaded the videos. Another 600,000 shared those videos with their friends. Most important, Melville stressed, is that 50% of the teens who engaged CHPA’s anti-abuse campaign were less likely to abuse in the future. 

And 25 states now mandate participation in the National Precusor Log Exchange (NPLEx), up from seven two years ago, Melville noted. NPLEx is consumer-friendly and a more-viable alternative to prescription-only in controlling pseudoephedrine sales.  

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES